Document is current
Any future updates will be listed below
-
Authors
Chew, Elaine GY https://orcid.org/0000-0001-9763-703X
Liu, Zhehao
Li, Zheng https://orcid.org/0000-0002-7060-2213
Chung, Sun Ju
Lian, Michelle M. https://orcid.org/0000-0001-6881-2660
Tandiono, Moses
Heng, Yue Jing
Ng, Ebonne Y.
Tan, Louis CS
Chng, Wee Ling
Tan, Tiak Ju
Peh, Esther KL
Ho, Ying Swan
Chen, Xiao Yin
Lim, Erin YT
Chang, Chu Hua
Leong, Jonavan J. https://orcid.org/0009-0004-3763-3888
Peh, Ting Xuan
Chan, Ling Ling
Chao, Yinxia
Au, Wing-Lok
Prakash, Kumar M.
Lim, Jia Lun
Tay, Yi Wen
Mok, Vincent https://orcid.org/0000-0002-8102-8835
Chan, Anne YY
Lin, Juei-Jueng
Jeon, Beom S.
Song, Kyuyoung
Tham, Clement C. https://orcid.org/0000-0003-4407-6907
Pang, Chi Pui
Ahn, Jeeyun
Park, Kyu Hyung
Wiggs, Janey L.
Aung, Tin
Tan, Ai Huey
Ahmad Annuar, Azlina
Makarious, Mary B. https://orcid.org/0000-0002-7978-1051
Blauwendraat, Cornelis https://orcid.org/0000-0001-9358-8111
Nalls, Mike A. https://orcid.org/0000-0003-0319-4325
Robak, Laurie A.
Alcalay, Roy N.
Gan-Or, Ziv
Reynolds, Richard
Lim, Shen-Yang
Xia, Yun
Khor, Chiea Chuen https://orcid.org/0000-0002-1128-4729
Tan, Eng-King https://orcid.org/0000-0003-2977-9743
Wang, Zhenxun https://orcid.org/0000-0002-7862-4636
Foo, Jia Nee https://orcid.org/0000-0001-9899-2308
- License Information
-
More Information
Article History
Received: 1 May 2024
Accepted: 24 October 2024
First Online: 21 November 2024
Competing interests
: Z.G.-O. received consultancy fees from Lysosomal Therapeutics, Idorsia, Prevail Therapeutics, Ono Therapeutics, Denali, Handl Therapeutics, Neuron23, Bial Biotech, Bial, UCB, Capsida, Vanqua Bio, Congruence Therapeutics, Takeda, Jazz Pharmaceuticals, Guidepoint, Lighthouse and Deerfield. R.N.A. received consultation fees from Biogen, Biohaven, Capsida, Gain Therapeutics, Genzyme/Sanofi, Janssen, Servier, SK Biopharmaceuticals, Takeda and Vanqua Bio. Y.X. holds a stock option in NeoCytogen Therapeutics where she is scientific co-founder and Chief Scientific Officer. M.A.N.’s participation in this project was part of a competitive contract awarded to DataTecnica, LLC by the National Institutes of Health to support open science research. M.A.N. also owns stock in Character Bio, Inc. and Neuron23, Inc. The other authors declare no competing interests.
